- Works count
- 414
- Citation count
- 10,117
- H-index
- 44
- i10-index
- 123
Research interests
Publications
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology · 2023 · 10.1016/j.annonc.2023.05.005
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30142-x
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
New England Journal of Medicine · 2019 · 10.1056/nejmoa1808424
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911361
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
PLoS ONE · 2017 · 10.1371/journal.pone.0186043
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Clinical Cancer Research · 2017 · 10.1158/1078-0432.ccr-16-2196
Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group
European Journal of Cancer · 2013 · 10.1016/j.ejca.2013.01.035
The intravascular volume effect of Ringer's lactate is below 20%: a prospective study in humans
Critical Care · 2012 · 10.1186/cc11344
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
International Journal of Gynecological Cancer · 2011 · 10.1097/igc.0b013e31820aaafd
Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease
Annals of Surgical Oncology · 2010 · 10.1245/s10434-010-0964-9
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
International Journal of Cancer · 2010 · 10.1002/ijc.25423
Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis
Annals of Surgical Oncology · 2009 · 10.1245/s10434-009-0357-0
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Gynecologic Oncology · 2007 · 10.1016/j.ygyno.2007.02.026
Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study
Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2769
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Annals of Surgical Oncology · 2006 · 10.1245/s10434-006-9058-0
Current projects
No projects listed.